Therapeutic Advances in Medical Oncology: 2023, vol: 15, issue:
- 1)- Géraldine Lens, Niloefar Ahmadi Bidakhvidi, Vincent Vandecaveye, Steven Grauwels, Annouschka Laenen, Wies Deckers, Ronald Peeters, Raphaëla C Dresen, Jeroen Dekervel, Chris Verslype, Kristiaan Nackaerts, Paul M Clement, Eric Van Cutsem, Michel Koole, Karolien Goffin, Koen Van Laere, Christophe M Deroose. Intra-individual qualitative and quantitative comparison of [Ga]Ga-DOTATATE PET/CT and PET/MRI. Therapeutic advances in medical oncology. 2023, 15: 17588359231189133
Cited : 0Read More - 2)- Huijuan Li, Hedong Han, Chuling Li, Ranpu Wu, Zhaofeng Wang, Yimin Wang, Ping Zhan, Tangfeng Lv, Fang Zhang, Yong Song, Hongbing Liu. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis. Therapeutic advances in medical oncology. 2023, 15: 17588359231189430Cited : 5Read More
- 3)- Frédérique Rousseau, Florence Ranchon, Christophe Bardin, Naoual Bakrin, Vincent Lavoué, Leila Bengrine-Lefevre, Claire Falandry. Ovarian cancer in the older patient: where are we now? What to do next? Therapeutic advances in medical oncology. 2023, 15: 17588359231192397Cited : 2Read More
- 4)- Zuzana Bielcikova, Lukas Werner, Jan Stursa, Vladimir Cerny, Ludmila Krizova, Jan Spacek, Stanislav Hlousek, Michal Vocka, Olga Bartosova, Michal Pesta, Katarina Kolostova, Petr Klezl, Vladimir Bobek, Jaroslav Truksa, Sona Stemberkova-Hubackova, Lubos Petruzelka, Pavel Michalek, Jiri Neuzil. Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial. Therapeutic advances in medical oncology. 2023, 15: 17588359231197957Cited : 0Read More
- 5)- Yu Ling Tay, Whee Sze Ong, Sherilyn Zi Hui Liew, Anupama Roy Chowdhury, Johan Chan, Mothi Babu Ramalingam, Tanujaa Rajasekaran, Tira J Tan, Lalit Krishna, Olive Lai, Agnes Lai Yin Chow, Simon Chen, Ravindran Kanesvaran. External validation of the first prognostic nomogram for older adults with cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231198433Cited : 0Read More
- 6)- Robert B Cameron, Jacobi B Hines, Valter Torri, Luca Porcu, Jessica Donington, Christine M Bestvina, Everett Vokes, James M Dolezal, Alessandra Esposito, Marina C Garassino. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Therapeutic advances in medical oncology. 2023, 15: 17588359231198446Cited : 1Read More
- 7)- Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A Gupta, David Shultz. Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study. Therapeutic advances in medical oncology. 2023, 15: 17588359231198943Cited : 2Read More
- 8)- Adam J Cohen-Nowak, Danielle B Dressler, Adam Rock, Katherine Mojica, Doni Woo, Lee M Zuckerman, Warren Chow, Mark Agulnik. Role of immunotherapy in chondrosarcoma: A case report and review of the literature. Therapeutic advances in medical oncology. 2023, 15: 17588359231199877Cited : 4Read More
- 9)- Mattea Reinisch, Simona Bruzas, Jennifer Spoenlein, Satyendra Shenoy, Alexander Traut, Hakima Harrach, Ouafaa Chiari, Efsthatia Cremer, Beyhan Ataseven, Lars Gubelt, Sherko Kuemmel. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Therapeutic advances in medical oncology. 2023, 15: 17588359231200454Cited : 8Read More
- 10)- Hyehyun Jeong, Sung-Bae Kim. Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy. Therapeutic advances in medical oncology. 2023, 15: 17588359231200457Cited : 0Read More
- 11)- Bernhard Doleschal, Patrick Kirchweger, Simon Schwendinger, Alexander Kupferthaler, Jonathan Burghofer, Gerald Webersinke, Emina Jukic, Helwig Wundsam, Matthias Biebl, Andreas Petzer, Holger Rumpold. Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231200462Cited : 0Read More
- 12)- Li-Na He, Tao Chen, Sha Fu, Yongluo Jiang, Xuanye Zhang, Chen Chen, Wei Du, Linfeng Luo, Anlin Li, Yixing Wang, Hui Yu, Yixin Zhou, Yuhong Wang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Wenfeng Fang, Li Zhang, Shaodong Hong. Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor. Therapeutic advances in medical oncology. 2023, 15: 17588359231200463Cited : 1Read More
- 13)- . Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231201818Cited : 0Read More
- 14)- Jinglong Huang, Caifeng Gong, Aiping Zhou. Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors. Therapeutic advances in medical oncology. 2023, 15: 17588359231204854Cited : 4Read More
- 15)- Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Therapeutic advances in medical oncology. 2023, 15: 17588359231204856Cited : 2Read More
- 16)- Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruner. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Therapeutic advances in medical oncology. 2023, 15: 17588359231204857Cited : 1Read More
- 17)- Dragica Pavlovic, Danijela Niciforovic, Dragana Papic, Katarina Milojevic, Marina Markovic. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Therapeutic advances in medical oncology. 2023, 15: 17588359231205848Cited : 5Read More
- 18)- Langbiao Liu, Lei Niu, Xue Zheng, Fei Xiao, Huaibo Sun, Wei Deng, Jun Cai. PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231205853Cited : 3Read More
- 19)- Youwen Zhu, Kun Liu, Hong Zhu, Hui Cao, Yangying Zhou. Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial. Therapeutic advances in medical oncology. 2023, 15: 17588359231206147Cited : 1Read More
- 20)- Jui Wan Loh, Abner Herbert Lim, Jason Yongsheng Chan, Yoon-Sim Yap. Classification of HER2-negative breast cancers by copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations. Therapeutic advances in medical oncology. 2023, 15: 17588359231206259Cited : 1Read More
- 21)- Qingyan Liu, Rong Li, Lingling Li, Gaokun Wang, Shiyu Ji, Xuan Zheng, Xiaodong Jia, Haitao Tao, Yi Hu. Efficacy and safety of anti-PD-1 monotherapy anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Therapeutic advances in medical oncology. 2023, 15: 17588359231206274Cited : 4Read More
- 22)- Xiongwen Yang, Yi Xiao, Yubin Zhou, Huiyin Deng, Zihao Yuan, Longyan Dong, Jun Lan, Hao Hu, Jian Huang, Shaohong Huang. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study. Therapeutic advances in medical oncology. 2023, 15: 17588359231206282Cited : 1Read More
- 23)- Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, Elizabeth L Christie, Dale W Garsed, Elizabeth Lieschke, Ksenija Nesic, Olga Kondrashova, Gayanie Ratnayake, Marc Radke, Jocelyn S Penington, Amandine Carmagnac, Valerie Heong, Elizabeth L Kyran, Fan Zhang, Nadia Traficante, , Ruby Huang, Alexander Dobrovic, Elizabeth M Swisher, Orla McNally, Damien Kee, Matthew J Wakefield, Anthony T Papenfuss, David D L Bowtell, Holly E Barker, Clare L Scott. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Therapeutic advances in medical oncology. 2023, 15: 17588359231208674Cited : 1Read More
- 24)- Alexander Georgakopoulos, Aristotle Bamias, Sophia Chatziioannou. Current role of PSMA-PET imaging in the clinical management of prostate cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231208960Cited : 3Read More
- 25)- Chii Yang Kuah, Robert Monfries, Matteo Quartagno, Michael J Seckl, Ehsan Ghorani. What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer? Therapeutic advances in medical oncology. 2023, 15: 17588359231210271Cited : 2Read More
- 26)- Yuan Yuan, Colt Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Lin, Helen Chang, Leslie Mi Ok Chong, Amanda Seiz, Monil Shah, W Hans Meisen, Aileen Tang, Norma Martinez, Wichanee Pickett, Mireya Murga, Susan E Yost, Daphne Stewart, Jianying Zhang, Nicholas Ede, Badri Modi, Jonathan Kessler, Jamie Rand, Yuman Fong. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study. Therapeutic advances in medical oncology. 2023, 15: 17588359231210675Cited : 1Read More
- 27)- Yuzhong Chen, Yuanjian Shi, Hanlin Ding, Yipeng Feng, Te Zhang, Yingkuan Liang, Hui Wang, Xuming Song, Bing Chen, Wenjie Xia, Qixing Mao, Bo Shen, Lin Xu, Gaochao Dong, Feng Jiang. Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy. Therapeutic advances in medical oncology. 2023, 15: 17588359231210678Cited : 0Read More
- 28)- Rasha Aboelhassan, Mohamed Emam Sobeih, Mohamed Alm El-Din, Ramy R Ghali, Ibtessam Saad El-Din, Ola Khorshid, Mohsen Mokhtar, Ahmed Magdy Rabea, Abdelaziz Belal, Hamdy A Azim, Mohamed Abdullah, Tamer Elnahas, Hesham Tawfik, Sherif Abdelwahab, Amr Abdelaziz Elsaid, Tarek Hashem, Mohamed Mancy, Heba Farag. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort. Therapeutic advances in medical oncology. 2023, 15: 17588359231212182Cited : 0Read More
- 29)- Alessandro Passardi, Irene Azzali, Alessandro Bittoni, Giorgia Marisi, Francesca Rebuzzi, Chiara Molinari, Giulia Bartolini, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Manlio Monti, Martina Valgiusti, Margherita Muratore, Ilario Giovanni Rapposelli, Paola Ulivi, Giovanni Luca Frassineti. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab. Therapeutic advances in medical oncology. 2023, 15: 17588359231212184Cited : 5Read More
- 30)- Sean J Huls, Brian Burkett, Eric Ehman, Val J Lowe, Rathan M Subramaniam, A Tuba Kendi. Clinical practice in prostate PET imaging. Therapeutic advances in medical oncology. 2023, 15: 17588359231213618Cited : 2Read More
- 31)- Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng. Cemiplimab combined with chemotherapy chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis. Therapeutic advances in medical oncology. 2023, 15: 17588359231213619Cited : 2Read More
- 32)- Ying-Tao Lin, Chong-Chong Zhou, Kai Xu, Meng-Die Zhang, Xin Li. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Therapeutic advances in medical oncology. 2023, 15: 17588359231213621Cited : 1Read More
- 33)- Ashkan Adibi, Ünal Metin Tokat, Eylül Özgü, Esranur Aydın, İrem Demiray, Mutlu Demiray. PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview. Therapeutic advances in medical oncology. 2023, 15: 17588359231213841Cited : 2Read More
- 34)- Li Zhang, Yongsheng Wang, Lizhu Lin, Yongfeng Yu, Shun Lu. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib. Therapeutic advances in medical oncology. 2023, 15: 17588359231216089Cited : 0Read More
- 35)- Kazuaki Harada, Satoshi Yuki, Yasuyuki Kawamoto, Takeaki Nakamura, Shiho Kaneko, Koichi Ishida, Naoya Sakamoto, Yoshito Komatsu. Anti-epidermal growth factor receptor treatment for patients with Neo wild-type metastatic colorectal cancer: a case report of two cases. Therapeutic advances in medical oncology. 2023, 15: 17588359231216090Cited : 2Read More
- 36)- Shuhui You, Yizhao Xie, Mengjing Ji, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shihui Hu, Yumeng Li, Zhongyi Yang, Biyun Wang. ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors. Therapeutic advances in medical oncology. 2023, 15: 17588359231216093Cited : 0Read More
- 37)- Komal Jhaveri, Joyce O'Shaughnessy, Peter A Fasching, Sara M Tolaney, Denise A Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S Rugo. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231216095Cited : 2Read More
- 38)- Qiwen Pan, Ruiqi Liu, Xinyue Zhang, Lingling Cai, Yilin Li, Pei Dong, Jianming Gao, Yang Liu, Liru He. CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. Therapeutic advances in medical oncology. 2023, 15: 17588359231217966Cited : 2Read More
- 39)- Shuhui You, Die Sang, Fei Xu, Ting Luo, Peng Yuan, Yizhao Xie, Biyun Wang. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study. Therapeutic advances in medical oncology. 2023, 15: 17588359231217972Cited : 0Read More
- 40)- Nicole O Williams, Dionisia Quiroga, Courtney Johnson, Adam Brufsky, Mara Chambers, Saveri Bhattacharya, Maria Patterson, Sagar D Sardesai, Daniel Stover, Maryam Lustberg, Anne M Noonan, Mathew Cherian, Darlene M Bystry, Kasey L Hill, Min Chen, Mitch A Phelps, Michael Grever, Julie A Stephens, Bhuvaneswari Ramaswamy, William E Carson, Robert Wesolowski. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer. Therapeutic advances in medical oncology. 2023, 15: 17588359231217976Cited : 1Read More
